替莫唑胺与司莫司丁对恶性脑胶质瘤的疗效对比观察  

Observation of Curative Effects of Temozolomide and Semustine on Malignant Gliomas

作　　者：曾宪起[1] 申长虹[1] 浦佩玉[1] 杨树源[2] 

机构地区：[1]天津市第三医院神经外科,天津300250 [2]天津市医科大学总医院神经外科,天津300070

出　　处：《中国临床神经外科杂志》2006年第6期333-335,共3页Chinese Journal of Clinical Neurosurgery

摘　　要：目的探讨替莫唑胺(TMZ)与司莫司丁(CCNU)治疗恶性脑胶质瘤的效果。方法恶性脑胶质瘤患者55例,经手术治疗后随机分成两组,按体表面积分别给以TMZ和CCNU治疗2￣6疗程,并每月进行临床随访、定期复查头颅增强CT或MRI,并与化疗前资料比较,判断病情变化。结果TMZ组有效率为44.74%,CCNU组为11.77%,两组相差显著(P<0.05)。结论TMZ比CCNU不仅能更好的改善恶性胶质瘤患者的临床症状,提高其生活质量,而且可更明显地缩小肿瘤体积。Objective To explore the curative effect of temozolomide （TMZ）, and semustine （CCNU） on malignant gliomas. Methods Fifty-five patients with malignant gliomas undergoing the surgery were randomly divided into two groups, i.e. TMZ treatment and CCNU treatment group, where the patients were treated respectively by TMZ and CCNU according to the body surface area. The clinical following-up and contrast-enhanced CT or GD-MRI examination were performed to evaluate the tumor progression. The data of the following-up and imagings after the chemotherapy were compared to those before the chemotherapy. Results The image-based response rates in TMZ and CCNU groups were 44.74% and 11.77% respectively. There was significant difference in the response rate between TMZ and CCNU groups （P〈0.05）. Conclusion TMZ can improve the patients with malignant gliomas in the symptoms and survival quality better, and produce higher response rate compared to CCNU in the patients with malignant gliomas after the surgery.

关 键 词：替莫唑胺(TMZ) 司莫司丁(CCNU) 恶性脑胶质瘤 

分 类 号：R739.41[医药卫生—肿瘤]